For the past decade, the most powerful cholesterol-lowering drugs in medicine have had one problem nobody could solve: they require an injection.
For millions of patients, that single barrier has been enough to stop them from using medications that could save their lives.
A new experimental pill called enlicitide may have just removed that barrier entirely.
Published this week in The New England Journal of Medicine, the phase three CORALreef Lipids trial tested enlicitide in 2,909 patients who either had established heart disease or were at serious risk of developing it. All participants were already taking statins. Most still couldn’t get their cholesterol to safe levels.
After 24 weeks on enlicitide, their LDL, the “bad” cholesterol that causes heart attacks and strokes, dropped by about 60% compared to patients on placebo.
Not 10%. Not 20%. Sixty.
Why This Number Is So Significant
To understand why 60% matters so much, you need to know a little about what came before.
Statins, the cholesterol drugs most people are familiar with, typically lower LDL by 30 to 50% depending on the dose and the patient. They have been the backbone of heart disease prevention for 40 years. They are cheap, widely available, and broadly effective.
But nearly 70% of patients with established heart disease still don’t reach their LDL targets on statins alone. For those patients, the next step has been injectable PCSK9 inhibitors, drugs like evolocumab and alirocumab, which lower LDL by about 60%.
Those injections work. They work extremely well. And despite a decade of evidence showing they save lives, the vast majority of primary care doctors still don’t prescribe them.
Dr. Ann Marie Navar, the cardiologist at UT Southwestern who led the CORALreef trial, has spent years studying why. Her answer: the injections.
“Even though prices have come down and insurance coverage has improved,” she said, “the vast majority of primary care physicians and a substantial minority of cardiologists still don’t prescribe them, possibly because they are only available as injections.”
Enlicitide works the same way as those injections. It binds to the same protein, PCSK9, which normally reduces the number of LDL receptors in the liver. Block PCSK9 and you get more receptors. More receptors means more LDL pulled out of the bloodstream. Less LDL means fewer heart attacks.
The only difference is that enlicitide does all of this in a daily pill.
The Numbers Behind the Trial
The CORALreef Lipids trial is large by any standard. Nearly 3,000 patients. 168 clinical sites. 14 countries. All participants were already on moderate-to-high-intensity statins at the start, meaning this is not a study of people who hadn’t tried other options.
The average LDL at baseline was around 96 mg/dL. Recommended targets for patients with established heart disease sit at 70 mg/dL or lower. For the highest-risk patients, guidelines suggest getting below 55 mg/dL.
At 24 weeks, the average LDL in the enlicitide group had dropped to 38.7 mg/dL. The placebo group barely moved, averaging 98.6 mg/dL.
That gap is enormous. And it held at 52 weeks, where enlicitide maintained a 47.6% reduction over placebo.
The drug also reduced non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), all markers associated with cardiovascular risk, by similar magnitudes. Safety outcomes were comparable between the two groups. No serious unexpected side effects emerged.
“These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,” Dr. Navar said.
What Enlicitide Still Needs to Prove
The CORALreef trial measured cholesterol numbers. It did not measure heart attacks, strokes, or deaths. Those are the outcomes that actually tell you whether a drug saves lives.
Lowering LDL almost always translates into reducing heart attacks, and the relationship is well-established across decades of research. But “almost always” is not the same as “definitively proven for this specific drug.”
A separate cardiovascular outcomes trial is already underway. It will study whether enlicitide’s dramatic LDL reductions actually translate into fewer heart attacks and strokes in real patients. Results are years away.
In the meantime, the FDA has granted enlicitide a National Priority Review Voucher, designed to accelerate the approval process for drugs that address serious conditions. That is not approval. It is a signal that the agency is treating this seriously.
Merck, which is developing the drug, has not yet filed for full FDA approval. That step is expected later this year.
The Nobel Prize Connection Nobody Is Mentioning
Enlicitide’s origins trace directly back to research conducted at UT Southwestern Medical Center in Dallas.
In the 1970s, Drs. Michael Brown and Joseph Goldstein discovered the LDL receptor on liver cells, the mechanism that removes LDL cholesterol from the blood. That discovery won them the Nobel Prize in Physiology or Medicine in 1985.
That same research eventually led to statins. Then to the PCSK9 protein discovery, made at UT Southwestern through the Dallas Heart Study. Then to injectable PCSK9 inhibitors. And now to enlicitide.
One Nobel Prize. Four decades of follow-on science. A daily pill that cuts bad cholesterol by 60%.
That is what compounding scientific progress looks like when it is allowed to run its course.
Why This Matters Right Now
Cardiovascular disease kills more people globally than any other cause. In the US, it accounts for roughly one in three deaths. The majority of those deaths involve atherosclerosis, the buildup of LDL-containing plaque in artery walls that eventually causes heart attacks and strokes.
An estimated 86 million American adults have high LDL cholesterol. Nearly 70% of high-risk patients don’t reach their LDL targets even with existing medications.
The gap between what is possible medically and what patients actually receive has been, for years, largely explained by the inconvenience of injections. Doctors hesitate to prescribe them. Patients hesitate to accept them. Insurance coverage has been inconsistent. The logistics have been off-putting enough to create a massive treatment gap in one of the deadliest disease categories in medicine.
Enlicitide does not solve all of those problems. But it removes the biggest one.
If it reaches market, and if real-world prescribing patterns respond to pill format the way everything we know about patient behavior suggests they will, the impact on heart attack and stroke rates could be significant.
Dr. Navar was unequivocal: “An oral therapy this effective has the potential to dramatically improve our ability to prevent heart attacks and strokes on a population level.”
That is a cardiologist who has spent her career watching people die of preventable heart disease, saying carefully chosen words about a drug she has spent years studying.
It is worth taking seriously.
About the Author
